Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Payables (2019 - 2025)

Vivos Therapeutics has reported Payables over the past 7 years, most recently at $1.7 million for Q4 2025.

  • Quarterly Payables rose 52.91% to $1.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.7 million through Dec 2025, up 52.91% year-over-year, with the annual reading at $1.7 million for FY2025, 52.91% up from the prior year.
  • Payables was $1.7 million for Q4 2025 at Vivos Therapeutics, down from $2.1 million in the prior quarter.
  • Over five years, Payables peaked at $2.5 million in Q1 2024 and troughed at $644000.0 in Q3 2022.
  • The 5-year median for Payables is $1.3 million (2021), against an average of $1.4 million.
  • Year-over-year, Payables surged 137.27% in 2023 and then plummeted 51.74% in 2025.
  • A 5-year view of Payables shows it stood at $920000.0 in 2021, then soared by 53.37% to $1.4 million in 2022, then surged by 52.02% to $2.1 million in 2023, then tumbled by 48.81% to $1.1 million in 2024, then surged by 52.91% to $1.7 million in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Payables are $1.7 million (Q4 2025), $2.1 million (Q3 2025), and $1.8 million (Q2 2025).